CD4 and cardiovascular disorder: Briefly, PWH 40–75 years of age on stable ART with a current CD4+ T cell count > 100 cells/mm3 and low-to-moderate traditional cardiovascular disease risk were randomized to pitavastatin versus placebo with longitudinal follow-up for cardiovascular events.